Published • loading... • Updated
Junshi Biosciences Announces Final Analysis Results of the Phase 3 NEOTORCH Study at ESMO Congress 2026
Summary by Globe Newswire
8 Articles
8 Articles
The Toronto Star+7 Reposted by 7 other sources
Junshi Biosciences Announces Final Analysis Results of the Phase 3 NEOTORCH Study at ESMO Congress 2026
Perioperative toripalimab plus chemotherapy demonstrated significant and durable improvements in event-free survival and overall survival in patients with resectable stage II-III non-small cell lung cancer.
·Toronto, Canada
Read Full ArticleCoverage Details
Total News Sources8
Leaning Left4Leaning Right2Center1Last UpdatedBias Distribution57% Left
Bias Distribution
- 57% of the sources lean Left
57% Left
L 57%
14%
R 29%
Factuality
To view factuality data please Upgrade to Premium
